Statera BioPharma (STAB)

Statera BioPharma Financial Statements


Statera BioPharma Financial Overview

Statera BioPharma's market cap is currently ―. The company's EPS TTM is $-0.779; its P/E ratio is -0.16; Statera BioPharma is scheduled to report earnings on November 14, 2022, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Sep 21Jun 21Mar 21Dec 20Sep 20
Income Statement
Total Revenue$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit$ -115.93K$ ―$ ―$ ―$ 0.00
EBIT$ -9.64M$ -669.24K$ -5.19M$ -3.71M$ -6.17M
EBITDA$ -9.64M$ -669.24K$ -5.19M$ -3.71M$ -6.17M
Net Income Common Stockholders$ -12.72M$ -659.51K$ -5.29M$ -4.23M$ -5.68M
Balance Sheet
Cash, Cash Equivalents and Short-Term Investments$ 151.91K$ 593.87K$ 9.45M$ 13.78M$ ―
Total Assets$ 98.04M$ 13.83M$ 750.01K$ 1.04M$ ―
Total Debt$ 1.13M$ 2.00M$ 15.59M$ 18.87M$ 0.00
Net Debt$ 982.48K$ 1.41M$ 6.14M$ 5.09M$ 0.00
Total Liabilities$ 23.84M$ 300.62K$ 5.42M$ 4.69M$ ―
Stockholders Equity$ 8.57M$ 74.12M$ -4.67M$ -3.66M$ ―
Cash Flow
Free Cash Flow$ ―$ ―$ -2.60M$ 3.28M$ ―
Operating Cash Flow$ ―$ ―$ -2.59M$ 3.28M$ ―
Investing Cash Flow$ ―$ ―$ -4.68K$ -3.02K$ ―
Financing Cash Flow$ ―$ ―$ 2.15M$ -3.00M$ ―
Currency in USD

Statera BioPharma Earnings and Revenue History

Statera BioPharma Debt to Assets

Statera BioPharma Cash Flow

Statera BioPharma Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis